摘要
目的观察重组人表皮生长因子治疗烧伤创面的疗效和安全性。方法采用开放性临床观察,选择同体、同深度、相近或对称部位烧伤创面、肉芽创面和慢性溃疡创面进行自身对照观察,在正规治疗的基础上,局部喷rhEGF或安慰剂,以创面愈合为指标,判断创面愈合时间,并观察创面动态愈合率及不良反应。结果重组人表皮生长因子治疗浅Ⅱ度创面、深Ⅱ度创面、残余肉芽创面、慢性溃疡,治疗组较对照组创面愈合时间分别提前为2.08d、3.00d、4.33d、4.80d,组间比较有统计学意义(P<0.01),未见明显的不良反应。结论rhFGF能够有效促进浅Ⅱ度创面、深Ⅱ度创面、残余肉芽创面及慢性溃疡创面的愈合,未发现明显的药物不良反应。
[Objective] To observe the clinical efficacy of recombinent human epidermal growth factor in treatment of burn wounds. [ Methods] The patients suffering from superficial Ⅱ burn wounds, deep Ⅱ burn wounds, granulation wounds and chronic ulcer wounds were subjected to the randomized auto-control trial. Each wound was divided into two parts, and the application of the drugs was random. Recombinent human epidermal growth factor solution was used in trial group and balm in control group. Dressing changed once each day. The dynamic healing rate in different time and healing time were observed. [Results] The healing time of all above-mentioned wounds was significantly shorter in recombinent human epidermal growth factor treated groups than the controls （P 〈0.01）. There was no obvious adverse reaction. [Conclusion] Recombinent human epidermal growth factor can promote the healing of Ⅱ burn wounds, granulation wounds and chronic ulcer wounds without obvious side effects.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2005年第17期2683-2685,共3页
China Journal of Modern Medicine
关键词
重组人表皮生长因子
烧伤
创面愈合
recombinent human epidermal growth factor
, bums
wound healing
